Whole genome sequencing identifies rare variants in ANK1, LRRN1, HAS1, and other genes and gene regulatory regions for stroke in type 1 diabetes

Anni A. Antikainen^{1,2,3}, Jani Haukka^{1,2,3}, Anmol Kumar^{1,2,3}, Anna Syreeni^{1,2,3}, Stefanie Hägg-Holmberg^{1,2,3}, Anni Ylinen^{1,2,3}, Elina Kilpeläinen⁴, Anastasia Kytölä⁴, Aarno Palotie^{4,5,6}, Jukka Putaala⁷, Lena M. Thorn^{1,2,3,8}, Valma Harjutsalo^{1,2,3}, Per-Henrik Groop^{1,2,3,9} and Niina Sandholm^{1,2,3}, on behalf of the FinnDiane Study Group

1. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland

2. Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

3. Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland

4. Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

5. Analytic and Translational Genetics Unit, Department of Medicine, Department of Neurology and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

6. The Stanley Center for Psychiatric Research and Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA

7. Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

8. Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

9. Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia

Corresponding Author:

Per-Henrik Groop, per-henrik.groop@helsinki.fi

Words: 5480

Tables: 3

Figures: 5

Abstract

- 1 Individuals with type 1 diabetes (T1D) carry a markedly increased risk of stroke, with distinct clinical and
- 2 neuroimaging characteristics as compared to those without diabetes. Therefore, we studied stroke genetics
- in individuals with T1D using whole-genome sequencing (N=571) and whole-exome sequencing (N=480). 3
- 4 We attempted replication of the lead discoveries in our T1D specific cohort using a genome-wide
- association study (N=3,945) and genotyping (N=3,600), and in the general population from the large-scale 5
- population-wide FinnGen project and UK Biobank summary statistics. We analysed the genome 6
- 7 comprehensively with single-variant analyses, gene aggregate analyses, and aggregate analyses on genomic
- windows, enhancers and promoters. We discovered T1D specific stroke loci on 4q33-34.1, SREBF1, and 8
- 9 ANK1; and stroke loci that likely generalize to the non-diabetic population on HAS1, LRRN1, UACA,
- 10 LTB4R, LINC01500 (promoter capture loop to DACT1), and TRPM2-AS promoter. We further validated
- the promoter with an in vitro cell-based assay. 11

12 Introduction

Stroke is a notable cause of mortality and long-term disability worldwide, with diabetes among the most 13 14 important risk factors. Specifically, the standardized incidence ratio is nearly 6-fold among individuals with diabetes compared to the general population^{1,2}. Furthermore, 537 million adults live with diabetes today 15 and the incidence is still rising (IDF Diabetes Atlas, 2021)³, highlighting the importance of diabetes as a 16 17 risk factor for stroke. Even though much of this trend is driven by an increase in obesity and insulin-resistant type 2 diabetes (T2D), the incidence of insulin-dependent type 1 diabetes (T1D) has increased as well^{4,5}. 18 19 T1D is a lifelong condition caused by an autoimmune reaction towards the pancreas and treated with daily insulin injections. Interestingly, differences regarding the stroke risk imposed by diabetes have been 20 observed between the two diabetes types. The strokes themselves may be of hemorrhagic (20%) or ischemic 21 (80%) origin and classified into even more specific subtypes. T1D increases the risk of both ischemic- and 22 23 hemorrhagic stroke^{6,7}, while the risk imposed by T2D has been estimated more modest for hemorrhagic strokes^{7,8}. Importantly, T1D predisposes individuals particularly towards cerebral small-vessel disease and 24 strokes of microvascular origin^{9,10}. Diabetes causes also other complications, of which diabetic kidney 25 disease (DKD) and severe retinopathy predict cerebrovascular disease in T1D¹¹. Understanding stroke 26 pathophysiology in diabetes is important for improving treatment and quality of life for individuals with 27 28 T1D.

Stroke heritability has been estimated to vary between 30% and 40% in the general population¹². To date, 29 30 126 common genomic loci have been associated with stroke with genome-wide significance, although partly lacking external replication: 65 common genomic loci had been associated with stroke, a stroke 31 subtype, or small vessel disease¹³, while recently, a large cross-ancestry genome-wide association study 32 (GWAS) meta-analysis proposed 61 novel genomic loci for stroke¹⁴. Stroke heritability varies greatly 33 depending on the subtype, with the largest heritability estimated for large artery atherosclerotic stroke and 34 35 the lowest for small vessel disease¹⁵. Associations at many of the known common stroke loci overlap with other cardiovascular phenotypes, e.g., coronary artery disease (CAD)¹². In addition, some of the stroke-36

associated genes have been linked to diabetic complications, e.g., *COL4A1* to DKD^{16,17}, or *SH2B3* to T1D itself^{12,18}. So far, very few studies have investigated genetic risk factors for stroke in diabetes^{19–21}, and no genome-wide studies on stroke exist in individuals with diabetes, although we previously speculated that there may be a heritable component as a history of maternal stroke was associated with hemorrhagic stroke in individuals with T1D²². On the other hand, genetic studies on CAD in diabetes have identified a few diabetes-specific loci^{23,24}, although still pending external replication, and have replicated three known general population CAD risk loci in diabetes: *CDKN2B-AS1*, *PSRC1* and *LPA*^{21,23,25}.

A substantial proportion of heritability remains unexplained for stroke^{12,15}. Importantly, stroke is a complex 44 phenotype with multiple subtypes, which complicates genetic studies and reduces statistical power. 45 Furthermore, some rare monogenic disorders have stroke as one of their manifestations^{12,13}. In fact, rare 46 genetic variants with minor allele frequency (MAF) of $\leq 1\%$ may significantly contribute to stroke 47 heritability. In GWASs, the imputation accuracy of rare variants may be limited, and largely depends on 48 the minor allele count (MAC) in the reference sample²⁶. Rare variants can be reliably studied with next-49 generation sequencing-based techniques such as whole-genome sequencing (WGS) and whole-exome 50 sequencing (WES). We have previously used WES to study low frequency variants for DKD²⁷, and 51 identified protein coding variants associated in lipid and apolipoprotein traits in $T1D^{28}$. In the general 52 53 population, novel stroke risk loci have been identified with WGS²⁹, although Jurgens et al. (2022) analyzed WES in the UK Biobank for cardiometabolic traits and did not discover exome-wide significant stroke risk 54 genes³⁰. 55

Here we studied stroke genetics with WGS and WES in individuals with T1D with multiple statistical approaches by focusing on rare and low-frequency genomic variants. We performed single variant and aggregate analyses both within genes and on intergenic regions. Gene aggregate analyses were performed separately for predicted protein truncating- and protein altering variants (PTV and PAV, respectively; omnibus test, SKAT-O), while genomic windows, enhancers and promoters were analyzed with a functional annotation weighted sliding-window approach (STAAR-O). We performed the analyses in

Finnish individuals with T1D and well-characterized stroke phenotypes. Historically, the Finnish 62 population has been isolated and, thus, represents a unique genetic background with enrichment of low-63 frequency deleterious variants³¹, which may in part enable the discovery of rare disease-associated 64 mutations. We aimed both to find stroke-risk loci specific to individuals with T1D, and to identify risk loci 65 generalizable to the non-diabetic population, since discovery of rare variants is more probable in a high-66 risk Finnish diabetic population. Finally, we performed cell-based in vitro experiments to further validate 67 a discovered promoter region. Altogether, here we report the first genome-wide study on stroke genetics in 68 69 diabetes.

70

71 **Results**

72 Single variant analyses

This study is part of the Finnish Diabetic Nephropathy (FinnDiane) Study³². We studied WGS in 571 and 73 74 WES in 480 non-related individuals with T1D, entailing 112 and 74 stroke cases, respectively (Table 1, Supplementary Fig. 1, 2). We sought for variants associated with stroke using fixed-effects score test 75 meta-analysis of WES and WGS data for variants available in both data sets, and Firth regression on variants 76 77 available only in the other (MAC > 5, Fig. 1). We discovered a suggestive stroke-risk locus, 4q33-34.1, with minimally adjusted additive inheritance model (4:170787127, p-value=8.83×10⁻⁸, MAF=3.7%, Table 2, 78 79 Fig. 2). We attempted replication in individuals with T1D in the FinnDiane GWAS data set (N=3,945), restricted to high imputation quality variants (r^{2} >0.80), where we had good statistical power (>80%) to 80 detect a nominal association with an odds ratio (OR) \geq 2.5 for additive low-frequency variants (MAF=1%) 81 (Extended Data Fig. 1). However, the variant 4:170787127 was unavailable for replication in the T1D 82 specific GWAS and in the FinnGen general population GWAS summary statistics (Supplementary Note). 83 84 A variant with the third lowest *p*-value on 4q33-34.1 did not replicate in T1D nor the general population 85 (Table 2).

As DKD is a common diabetic complication that has been reported to predict incident stroke in T1D¹¹, we 86 performed additional analyses adjusted for DKD, and discovered a rare missense mutation on SREBF1 87 exome-wide significantly (p-value $<3\times10^{-7}$) associated with stroke (rs114001633, p.Pro227Leu, p-88 value=7.30×10⁻⁸, MAF=0.26%) (Extended Data Fig. 2, Table 2). In the stroke subtype analysis for the 89 lead findings, this variant was genome-wide significant for hemorrhagic stroke (p-value= 8.96×10^{-9} , 90 MAC=3, Supplementary Table 1). However, rs114001633 did not pass the MAC threshold in the stroke 91 92 subtype analysis (MAC > 5), thus, the result must be interpreted with caution. Due to the rarity of the variant, we performed additional genotyping for replication, whereby the variant replicated for hemorrhagic stroke 93 94 (*p*-value=0.02, N=3,263).

95 Recessive variants can have high mutation severity in comparison to e.g., autosomal dominant variants³³. Therefore, we further considered a recessive inheritance model and identified a genome-wide significant 96 variant on DHX8 intron with the minimal adjustment (rs1728177, p-value=7.19×10⁻⁹, MAF=26%) 97 (Extended Data Fig. 3, Table 2), which however did not replicate. Furthermore, we found two suggestive 98 99 recessive loci, including one with the minimal adjustment on 5' untranslated region (UTR) of LTB4R (rs2224123, p-value=4.77×10⁻⁷, MAF=14%). rs2224123 did not replicate in T1D but was borderline 100 101 significant in the general population with an additive model (FinnGen GWAS: p-value=0.052). In the sequencing data, significance with an additive model was nominal (p-value=0.019), suggesting that 102 103 rs2224123 acts recessively, but recessive data were not available for the replication look-up in the general 104 population.

105 Gene aggregate analyses

106 In order to improve statistical power for rare (MAF \leq 1%) and low-frequency (MAF \leq 5%) variants, we performed gene aggregate analyses with an optimal unified sequence kernel association test (SKAT-O) and 107 aimed to identify combined exonic variant effects associated with stroke in two distinct classes: PAV and 108 109 PTV i.e. the more severe putative loss-of-function variants³⁴ (Supplementary Note). We required a cumulative MAC (CMAC) ≥5 across the included variants in each gene. In the minimally adjusted model, 110 low-frequency PAVs on ANK1 were significantly associated with stroke (p-value=2.23×10⁻⁶, CMAC=247), 111 even more strongly with ischemic stroke (p-value= 1.31×10^{-6} , CMAC=225) (Fig. 3A, Extended Data Fig. 112 4, Supplementary Tables 2 and 3). Furthermore, the aggregate of low-frequency or rare PAVs was 113 suggestively associated with stroke in nine genes (Fig. 3A). Of these, TARBP2 associated significantly with 114 ischemic stroke (p-value= 1.71×10^{-7} , CMAC=5, MAF $\leq 1\%$), and CLEC4M with hemorrhagic stroke (p-115 value=4.74×10⁻¹⁵, CMAC=11, MAF≤1%). 116

117 After additional DKD adjustment, rare PAVs in *LRRN1* were significantly associated with stroke (p-118 value=3.49×10⁻⁶, CMAC=15), more strongly with ischemic stroke (p-value=8.69×10⁻⁶, CMAC=12; Fig.

3B, Extended Data Fig. 5, Supplementary Tables 2 and 4). Furthermore, we identified suggestive genes,
missed in the minimally adjusted model: *MAP3K12* and *MTRNR2L7*. In the stroke subtype analysis, rare
PAVs in *MAP3K12* were significantly associated with ischemic stroke (*p*-value=1.72×10⁻⁷, CMAC=17),
and in *MTRNR2L7* with hemorrhagic stroke (*p*-value=2.24×10⁻⁶, CMAC=6). *MAP3K12* and *TARBP2* are
located close to each other on the genome, thus, they may represent the same association signal through
linkage disequilibrium (LD) or modifier effects onto the causal gene (Supplementary Fig. 3).
The aggregate of PTVs was suggestively associated with stroke in two genes including hyaluronan synthase

126 1 (*HAS1*; Fig. 3A, Supplementary Table 3). In analysis for stroke subtypes, *HAS1* associated significantly

- 127 with ischemic stroke (*p*-value=7.39×10⁻⁷, CMAC=7). With additional DKD adjustment, rare PTVs in *HAS1*
- 128 (p-value=3.11×10⁻⁵) and UACA (p-value=6.77×10⁻⁵, CMAC=6), and low-frequency PTVs in ARPC5 (p-
- value=4.15×10⁻⁵, CMAC=39), were significantly associated with stroke (**Fig. 3B**, **Supplementary Table**
- 130 4).
- 131 Replication of gene aggregate findings

132 Most variants within the lead genes are rare or ultra-rare (MAF $\approx 0.1\%$), making replication with imputed genomic data problematic. Nevertheless, we attempted replication of the significant gene aggregate 133 134 discoveries within the FinnDiane GWAS data by including also five directly genotyped rare variants; 135 replication analyses were performed with SKAT-O. We also attempted replication for the variants 136 individually but had only limited power to detect an association even with nominal significance (pvalue<0.05) for variants with MAF=0.1% and OR<9 (Extended Data Fig. 1). Nevertheless, ANK1 and 137 138 LRRN1 showcased weak evidence of replication in T1D. Although ANK1 did not reach significance with SKAT-O (Supplementary Table 5), one of the available fifteen variants was significant for stroke 139 (rs779805849, *p*-value=0.01), and two additional variants replicated for hemorrhagic stroke (rs146416859 140 141 and rs61753679, p-value<0.05) (Table 3, Fig. 4, Supplementary Table 3). LRRN1 did not replicate in FinnDiane with rare PAVs (p-value=0.50, N_{variant}=4) (Supplementary Table 6). However, when we 142

extended the model to low-frequency PAVs (**Supplementary Table 6**), thus improved statistical power and imputation quality, *LRRN1* replicated for ischemic stroke after DKD adjustment (*p*-value=0.039, N_{variant}=6) in line with the sequencing analyses indicating an association with ischemic stroke. *UACA* contained two rare PTVs associated with stroke, of which one replicated through genotyping (*p*value=0.0030, **Supplemental Table 4**). However, the variant was ultra-rare (MAC=1), and replication thus uncertain. *ARPC5* did not replicate in T1D. In addition, we were unable to replicate *HAS1* in T1D due to missing data; we directly genotyped one variant but found no rare allele carriers.

We further attempted replication in the general population by look-ups from two UK Biobank general population WES studies^{30,35} (**Supplementary Tables 7 and 8**). Importantly, *HAS1* replicated for stroke in both studies with ultra-rare loss-of-function variants (MAF \leq 0.1%: Jurgens et al. *p*-value=0.039³⁰; Backman et al. *p*-value=0.035³⁵), while *UACA* replicated only in the latter study (MAF \leq 0.01%: Backman et al. *p*value=0.035³⁵). Finally, *LRRN1* replicated for stroke with an ultra-rare missense variant model (MAF \leq 0.001%: Backman et al. *p*-value=0.026³⁵), although not for ischemic stroke. Of note, *ANK1* did not replicate in the general population.

Out of the suggestive genes, *FOXO1*, *TARBP2*, and *MAP3K12* showcased weak replication in T1D (FinnDiane GWAS) (**Supplementary Tables 3, 4 and 5**). One variant within *FOXO1* replicated for hemorrhagic stroke (*p*-value=0.012), two within *MAP3K12* for hemorrhagic stroke (*p*-value=0.013); and *TARBP2* replicated for hemorrhagic stroke with SKAT-O (*p*-value=2.59×10⁻⁴). UK Biobank general population gene burden WES analysis look-ups supported stroke associations for *UTS2*, *MAP3K12*, and *FOXO1* (**Supplementary Table 8**)^{30,35}, while one variant within *RRP9* replicated for stroke in the FinnGen summary statistics.

164 Known Mendelian stroke genes in T1D

Mutations on Mendelian stroke risk genes may for instance cause small vessel disease or cerebral cavernous
 malformations, which can eventually lead to stroke¹². We inspected the association of 17 autosomal genes

167 previously linked to stroke through nonsynonymous mutations³⁶, and found 3 to also associate with stroke 168 in T1D (*p*-value<0.05; **Extended Data Fig. 6**). Rare PAVs on *KRIT1* associated with stroke (*p*-169 value=0.018), particularly with ischemic stroke (*p*-value=0.0092). Furthermore, rare PAVs on *ADA2* and 170 on *TREX1* associated with hemorrhagic stroke (*p*-value=0.027 and *p*-value=0.010, respectively). Loss-of-171 function mutations on *KRIT1* cause vascular malformations, while *ADA2* has been linked to 172 autoinflammatory small vessel vasculitis and *TREX1* to small vessel disease^{12,36}.

173 Sliding window analyses

174 In GWASs, roughly 88% of the identified disease-associated variants are located within non-coding regions³⁷. To increase statistical power to detect low-frequency and rare variants on non-coding regulatory 175 regions, we performed genome-wide sliding-window aggregate analyses within 4,000 base pair (bp) 176 regions, by statistically up-weighting functionally important variants according to Combined Annotation-177 Dependent Depletion (CADD) functional annotations and rarity with STAAR-O^{38,39} (Extended Data Fig. 178 7). We found further evidence for the 4q33-34.1 genomic region as we discovered fourteen windows, within 179 the extended region, with a genome-wide significant association between an aggregate of low-frequency 180 181 variants and stroke (Supplementary Table 9, Fig. 5A). Importantly, two of these windows (4:170782001-170786000, p-value=3.40×10⁻⁸, CMAC=934; and 4:170784001-170786000, p-value=1.10×10⁻⁸, 182 CMAC=1190) and ten individual variants within the 4q33-34.1 genomic region replicated for stroke in T1D 183 184 (FinnDiane GWAS: p-value<0.05; Supplementary Table 10). To identify the most likely effector genes for the 4q33-34.1, we inspected variant expression quantitative trait loci (eQTL) from GTEx Portal and 185 eOTLGen Consortium⁴⁰, and functional genomics from 3D Genome Browser⁴¹. 4q33-34.1 is located in the 186 same topologically associating domain with distal promoters of GALNTL6, MFAP3L and AADAT in the 187 frontal lobe and hippocampus (Supplementary Fig. 4). In addition, promoter capture high-throughput 188 189 chromosome conformation capture (PCHi-C) links could be identified for a few individual variants, e.g., for GALNTL6 in the hippocampus, and AADAT and MFAP3L in the dorsolateral prefrontal cortex. Several 190

variants were eQTLs for *LINC02431* in testis. In addition, one variant was a significant eQTL of *AADAT*in esophagus (normalized effect size [NES] =-0.55); and a nominal eQTL in many other tissues.

193 When we inspected rare variants (MAF <1%), we discovered multiple suggestive windows, e.g., close to or within the CNTN1, CNTN4, LINC01500, and TGOLN2 genes (Supplementary Table 9, Fig. 5B). In stroke 194 195 subtype analysis, the CNTNI window was genome-wide significant for hemorrhagic stroke (12:40950001-196 40954000: p-value=2.10×10⁻⁸, CMAC=24). Interestingly, CNTN1 and CNTN4 are located on different chromosomes, but belong to the same protein family encoding contactins⁴²; however, replication is still 197 pending. Importantly, a suggestive window near LINC01500 (14:59004001-59008000: p-value=2.53×10⁻⁷, 198 199 CMAC=19) replicated for stroke in T1D (FinnDiane GWAS: p-value=0.01, CMAC=24). Four variants 200 within the window were available in the FinnGen GWAS, and one replicated (rs1281241634, p-value=0.03) 201 (Supplementary Table 10). According to PCHi-C, the LINC01500 intronic window looped to the DACT1 202 promoter on the dorsolateral prefrontal cortex (Supplementary Fig. 5). Finally, the TGOLN2 window replicated for hemorrhagic stroke in T1D (FinnDiane GWAS: p-value=0.037). 203

204 **Promoters and enhancers**

205 As a more targeted approach to explore the non-coding regulatory genome, we studied rare and low-206 frequency variants in established regulatory regions - enhancers and promoters - as defined in FANTOM5 cap analysis of gene expression (CAGE) human raw data⁴³⁻⁴⁵, with promoters defined as the transcription 207 start site (TSS) extended to 1,000 bp. We discovered three enhancers with suggestive stroke-associated 208 enrichment of rare or low-frequency variants within intronic regions of TRPM3, LOC105378983, and 209 210 BDNF, encoding brain-derived neurotrophic factor (Supplementary Tables 11 and 12, Extended Data Fig. 8). Regional aggregate replications were not possible in the T1D specific GWAS ($N_{variant} < 2$). In 211 212 addition, individual variants were missing or did not replicate. PCHi-C linked the BDNF enhancer to its promoter on the dorsolateral prefrontal cortex and hippocampus (Supplementary Fig. 5). The BDNF 213 enhancer was significant after multiple testing correction for ischemic stroke (p-value=1.01×10⁻⁶). 214

215 We did not identify stroke-associated promoters after multiple testing correction (*p*-value $<3 \times 10^{-7}$). Extended Data Fig. 9). The strongest associations were two TGOLN2 promoters (p-value=5.60×10⁻⁶, 216 CMAC=9, MAF<1%), located on the previously mentioned TGOLN2 window, and a TRPM2-AS promoter 217 (p-value=5.78×10⁻⁶, CMAC=33, MAF≤1%; Supplementary Tables 13 and 14). TGOLN2 promoters were 218 borderline significant for ischemic stroke (p-value=4.71×10⁻⁷, MAC=5), but did not replicate in T1D. 219 TRPM2-AS promoter nearly replicated in T1D (FinnDiane GWAS: p-value=0.053). When we inspected 220 221 variants individually, one out of nine available variants replicated in the general population for ischemic stroke (FinnGen GWAS: p-value=0.038). In GTEx, rs762428 within the TRPM2-AS promoter associated 222 significantly to TRPM2 level in whole blood (NES=-0.63) and lungs (NES=-0.41, p < 0.001), also nominally 223 in other tissues such as the hypothalamus (NES=-0.42). TRPM2 encodes a calcium-permeable and non-224 selective cation channel expressed mainly in the brain⁴⁶, which has been linked to ischemic stroke and 225 belongs to the same melastatin subfamily as the previously mentioned TRPM3^{46,47}. TRPM2 inhibitors have 226 been proposed as a drug target option for central nervous system diseases⁴⁸, thus, our results suggested that 227 228 these inhibitors could be beneficial also for stroke in T1D.

Our cell-based experimental research on the TRPM2-AS promoter detected TRPM2-AS and TRPM2 229 transcripts specifically in HELA cells among tested cell-lines (Extended Data Fig. 10). Luciferase 230 231 promoter analysis of the TRPM2-AS promoter in HELA cells indicated strong promoter activity; although, the most strongly stroke-associated variant, rs753589764, did not significantly affect luciferase activity 232 233 under normal cell culture conditions (p-value=0.27, 22 technical repeats). However, we cannot rule out a variant effect under cellular stress, e.g., oxidative stress; a hallmark of cardiovascular disease in T1D⁴⁹. 234

235 **Discussion**

Stroke heritability has been estimated to range between 30% and 40%, but the genomic loci identified thus far explain only a small fraction of heritability¹². One potential explanation underlying the missing heritability are rare variants missed by GWAS. Therefore, we performed WES and WGS in a total of 1,051 Finnish individuals with T1D to discover rare and low-frequency variants associated with stroke and its major subtypes, either specific for T1D, or generalizable to the non-diabetic population. We identified multiple significant loci with evidence of replication, including protein altering or truncating variants on *ANK1*, *HAS1*, *UACA*, and *LRRN1*, as well as a 4q33-34.1 intergenic region.

With single variant analyses, we identified a suggestively stroke-associated missense mutation on SREBF1 243 (rs114001633, p.Pro227Leu) with an additive inheritance model adjusted for DKD, which was genome-244 wide significant for hemorrhagic stroke, and further replicated for hemorrhagic stroke. Variant penetrance 245 was 8% in replication, i.e., 1 out of 12 individuals carrying the risk allele developed hemorrhagic stroke. 246 247 As the variant was ultra-rare, and we had a relatively small number of hemorrhagic stroke cases, further replication is needed in T1D to conform this finding. SREBF1 encodes a transcription factor involved in 248 lipid metabolism and insulin signaling⁵⁰. In addition, we found a suggestively stroke-associated recessive 249 250 variant near LTB4R, encoding the leukotriene B4 receptor, which nearly replicated in the general population with an additive inheritance model. Importantly, recessive replication is still pending. 251

Gene aggregate tests (SKAT-O) detected four genes with significant stroke-associated burden of PAVs (*ANK1* and *LRRN1*) or PTVs (*HAS1* and *UACA*) and evidence of replication; *LRRN1*, *HAS1*, and *UACA* after adjustment for DKD. *ANK1* did not replicate in T1D with SKAT-O, however, one out of the fifteen available variants replicated for stroke in T1D (rs779805849, p.Val136Glu). Of note, SIFT and PolyPhen predicted many *ANK1* variants as deleterious^{51,52}. *ANK1* encodes ankyrin-1, within which mutations cause hereditary spherocytosis⁵³. Previous genome-wide association studies have linked the gene to T2D⁵⁴, while another gene from the ankyrin protein family, *ANK2*, is a previously identified stroke risk locus⁵⁵. Rare

259 PAVs in LRRN1 associated with ischemic stroke. LRRN1 did not replicate with the corresponding model in T1D, however; with a model extended to low-frequency PAVs, LRRN1 replicated for ischemic stroke. 260 261 Rare variant replication is problematic with GWAS data due to the uncertainty of the imputation, which may explain the need of increasing the allele frequency threshold to observe a successful replication. 262 263 Furthermore, *LRRN1* replicated with ultra-rare variants in the general population (UK Biobank WES: MAF ≤ 0.001%, p-value=0.025)³⁵. LRRN1 encodes leucine rich repeat neuronal protein 1, with a brain-264 265 enriched expression profile. HAS1 consistently replicated in the general population (UK Biobank WES: MAF $\leq 0.1\%$, p-value=0.012; MAF $\leq 1\%$, p-value=0.035)^{30,35}, while UACA replicated in one study with ultra-266 rare variants (UK Biobank WES: MAF < 0.01%, p-value=0.035)³⁵. HAS1 encodes an enzyme producing 267 268 hyaluronan and with expression induced by inflammation and glycemic stress⁵⁶. Of note, an increased hyaluronan turnover has been suggested to follow ischemic stroke⁵⁷. HAS1 replication was not feasible in 269 T1D due to absent mutation carriers, thus, a diabetes-specific replication is pending. Nevertheless, HAS1 270 PTVs may be of particular importance in T1D; dysregulation of endothelial glycocalyx hyaluronan has 271 been suggested to contribute to diabetic complications⁵⁸. Finally, it must be noted that PTVs have not been 272 functionally confirmed as loss-of-function, but the annotations are predictions; PTV at the beginning of a 273 gene is likely more severe than at the end, and in fact, PTVs nearer to the HAS1 transcription start site were 274 275 more strongly associated with stroke.

It has been suggested that disease-associated single nucleotide variants are more likely to occur on 276 intergenic regulatory regions than on exons³⁷. To increase statistical power on regulatory regions, we 277 performed statistical aggregate tests in genomic windows, enhancers and promoters^{38,45}. Of note, we 278 extended genomic window length from the default to increase statistical power, which however also 279 280 reduced precision as the causal region might be narrower. We found fourteen genome-wide significant 281 stroke-associated windows with low-frequency variants on 4q33-34.1, of which two replicated for stroke 282 in T1D. According to eQTLs and PCHi-C interactions, 4q33-34.1 variants most likely target GALNTL6, MFAP3L or AADAT, which encodes α -aminoadipate aminotransferase. We also discovered a suggestive 283

284 stroke-associated window within LINC01500, which replicated for stroke in T1D. According to PCHi-C, the LINC01500 window targets a promoter of DACT1, encoding a Wnt signaling repressor⁵⁹. Finally, we 285 286 identified a suggestive stroke-associated promoter of TRPM2-AS, which nearly replicated in T1D (pvalue=0.053). Importantly, transient receptor melastatin 2 (TRPM2) has been previously associated with 287 ischemic stroke⁴⁸. Our functional cell-based assay validated the promoter activity of the *TRPM2-AS* region. 288 289 However, the most strongly stroke-associated variant, rs753589764, did not associate with TRPM2-AS 290 promoter activity in normal cell culture conditions. Interestingly, rare variants on an enhancer region within 291 TRPM3 gene – from the same protein family but on a different chromosome – associated suggestively with stroke ($p=1.34 \times 10^{-5}$). 292

293 Limitations of the study include the limited statistical power at the discovery stage, especially for the stroke subtypes, and replication of rare variants with imputed GWAS data. We were able to improve the statistical 294 power on exomes by meta-analyzing WES and WGS, and we performed stroke-subtype specific analyses 295 only for a limited number of suggestive findings to avoid spurious signals due to unstable statistical 296 297 estimates. To further improve statistical power, we performed statistical aggregate tests on gene exons and on intergenic regions, i.e., enhancers, promoters, and genomic windows. Of note, we studied only 298 transcribed enhancers, and thus, some enhancers could have been missed. We defined promoters with an 299 300 arbitrarily selected 1,000 bp extension downstream TSS, which may not have always been optimal as the promoter lengths vary. A further limitation is the lack of sequencing-based replication data in individuals 301 with T1D. Instead, we sought for replication by combining available data sources, i.e., FinnGen (Finnish 302 303 general population GWAS), UK Biobank (general population WES), and FinnDiane (GWAS and genotyping in Finnish individuals with T1D). 304

The strengths of this study include a well characterized cohort and comprehensively performed single variant and aggregate analyses both for the coding and non-coding regions of the genome. Stroke is a challenging phenotype to address with ICD codes and many loci associated with rare stroke phenotypes may go unnoticed even with large population-wide genetic studies. We performed analyses for well-defined

- 309 stroke phenotypes verified by trained neurologists. Furthermore, as we conducted the analyses in specific
- 310 high-risk individuals from an isolated population, thus with lesser genetic and phenotypic diversity, we had
- 311 improved statistical opportunities to identify genetic risk loci.
- 312 In conclusion, we studied rare and low-frequency stroke-associated variants with WES and WGS in
- 313 individuals with T1D and report the first genome-wide study on stroke genetics in diabetes. The results
- highlight 4q33-34.1, SREBF1, and ANK1 for stroke in T1D; and HAS1, UACA, LRRN1, LINC01500, and
- 315 *TRPM2-AS* promoter as stroke risk loci that likely generalize to the non-diabetic population.

316 Methods

317 Participants and stroke definitions

The study is part of the FinnDiane Study established to investigate complications of T1D. We have access 318 319 to 490 and 583 non-related individuals with T1D with WES and WGS, respectively. Individuals in the present study were diagnosed with T1D by their attending physician and had diabetes onset age <40 and 320 insulin initiated within one calendar year from the diabetes diagnosis. Stroke phenotypes were identified 321 322 from the Finnish Death Registry, Statistics Finland, and the Care Register for Health Care, Finnish Institute 323 for Health and Welfare until the end of 2017 and were verified by trained neurologists from medical files and brain imaging data. We required acute stroke events to have occurred after the T1D diagnosis. For 324 individuals without data verified by neurologists available (N_{WGS}=27, N_{WES}=2), we considered only the 325 registry data, and excluded five controls with transient ischemic attacks or other intermediate stroke 326 phenotypes due to potential for misclassification (Supplementary Note). Furthermore, we classified stroke 327 328 events into ischemic- and hemorrhagic strokes whenever stroke subtypes verified by neurologists were available. Ischemic strokes entailed lacunar-, non-lacunar-, and unclear infarctions, while hemorrhagic 329 330 strokes comprised intracerebral and subarachnoid hemorrhages. We limited controls to individuals with 331 >35 years of age and >20 years of diabetes duration, because only ~5% of cases had experienced their first stroke event before these limits in sequencing data (Table 1, Supplementary Table 15). 332

333 Sequencing material

In total, 599 individuals were whole genome sequenced at Macrogen Inc. using the Illumina HiSeq X platform (Macrogen Inc., Rockville, MD, USA) with at least 30× average coverage (1-8 lanes). Furthermore, 502 participants were whole-exome sequenced at the University of Oxford, UK, as described earlier²⁷. In short, libraries were multiplexed and captured with Illumina TruSeq[™] Exome Enrichment Kit and sequenced on an Illumina HiSeq2000 with 100 bp paired end reads (1-2 lanes). Seven samples did not pass the initial quality control (QC) or showed discrepancies with other genetic data. For this work, the pre-

340 processed aligned reads of 495 individuals were converted back to unaligned FASTQ-reads and re341 processed with comparable pipeline to WGS.

First, we trimmed the WES and WGS sequencing reads⁶⁰. We processed 495 WES and 599 WGS samples 342 further according to Broad Institute's best practices guidelines with Genome Analysis Toolkit 4 (GATK4)⁶¹ 343 (Supplementary Fig. 6): We aligned reads by lane to GRCh38 reference genome with Burrows-Wheeler 344 345 Aligner, sorted and marked duplicate reads, recalibrated bases by chromosome, and called variants by 346 sample. WES and WGS were joint called separately. We filtered variants according to excess heterozygosity threshold of 54.69, truth sensitivity level 99.7%, and GATK's recommended tranche 347 thresholds for SNPs and indels. We assessed sample concordance with FinnDiane GWAS data whenever 348 possible. Finally, 490 and 583 individuals passed QC within WES and WGS, respectively. In variant QC, 349 for autosomal variants, we required Hardy-Weinberg equilibrium (HWE) p-value >10⁻¹⁰ and variant call 350 rate >98%; and for X chromosome variants, only variant call rate >98%. We annotated variants with 351 SNPEff v.5 software⁶². WES and WGS comprised 324,817 and 21.92 million variants, respectively. 352

353 **Replication material**

354 In FinnDiane, we have GWAS data for 6,458 Finnish individuals with T1D and their relatives. Genomes were genotyped at the University of Virginia, and previously processed to GRCh37 reference genome⁶³. 355 356 We shifted the genotyping positions to GRCh38, re-imputed the data to SISu v3 reference panel, and annotated with SNPEff v.5 software⁶² (Supplementary Fig. 7). We restricted the data to 15,026,805 high 357 imputation quality variants ($r^2 > 0.80$), and individuals to those with T1D; age at onset <40 years and insulin 358 359 treatment initiated within two years from diagnosis, if insulin initiation year known, and to those not in the 360 sequencing data. Controls were required to have diabetes duration >20 years and age >35 years. GWAS 361 replication entailed 367 cases and 3,578 controls (Supplementary Fig. 8, Supplementary Tables 16 and 17). Instead of principal component adjustment, we utilized rvtests kinship matrix with Balding-Nichol's 362 approximation in single variant analysis and GEMMA relatedness matrix in aggregate analyses⁶⁴⁻⁶⁶. 363

Twelve lead variants were selected for replication by variant genotyping in 3,600 FinnDiane participants with T1D on one Agena iPlex multiplexing assay at the Institute for Molecular Medicine Finland, Helsinki, Finland (**Supplementary Table 18**). Variants were prioritized onto to the same multiplexing design based on statistical significance, and one heterozygous variant carrier within sequencing data included as the positive control. Replication was limited to individuals within GWAS data to perform relatedness adjustment with kinship matrix (N=3,263, **Supplementary Table 19, Supplementary Fig. 9**).

370 Statistical methods

371 Single variant analyses

We analyzed variants available in WES and WGS data with score test fixed-effect inverse variance based meta-analysis (CMAC \geq 5, WES and WGS: MAC \geq 2), and variants only available in one of the data sets with Firth regression (MAC \geq 5). Furthermore, autosomal variants were analyzed recessively according to similar scheme (cumulative homozygote minor allele carriers \geq 5; WES and WGS homozygote carriers \geq 2). Analyses were carried out with rvtests (version 20190205)⁶⁵ and metal (version 20110325)⁶⁷, except autosomal recessive Firth regression with plink2 (version 20210420)^{68,69}.

378 Gene aggregate analyses

We performed autosomal gene aggregate tests with SKAT-O, combining burden and variance-component 379 tests, with the aim to increase statistical power and stability⁷⁰. We performed SKAT-O meta-analysis, 380 381 separately with PAVs and PTVs, between WES and WGS using MetaSKAT (version 0.81)⁷¹, which exploits single variant score statistics. PTVs were here defined as predicted loss-of-function mutations 382 (Supplementary Note). PAV analyses entail, in addition to the PTVs, mutations that are predicted to alter 383 amino acid sequence. Only variable sites (MAC>1) were accepted into gene aggregate ($N_{variant}>2$, 384 CMAC≥5). We did not report genes with all variants in perfect LD, and inspected individual variant stroke-385 associations within the genes using score test fixed-effects meta-analysis^{65,67}. Multiple testing correction 386

based on number of included genes resulted in significance thresholds of *p*-value $<4\times10^{-6}$ for PAVs (MAF $\leq1\%$ and MAF $\leq5\%$), *p*-value $<7\times10^{-5}$ for PTVs with MAF $\leq1\%$, and *p*-value $<5\times10^{-5}$ for PTVs with MAF $\leq5\%$. For the known Mendelian stroke risk genes³⁶, we reported results regardless of variant number or CMAC.

391 Sliding-window analyses and regulatory regions

392 We performed functional annotation weighted sliding window analyses on the WGS data with the STAAR R package 0.9.6³⁸. For variant annotations we utilized CADD v1.6 GRCh38 data^{39,72}, more specifically; 393 variant MAF (to up-weight rarer variants), pre-computed CADD score, and the first annotation principal 394 components from seven annotation classes (Extended Data Fig. 7, Supplementary Note). Following 395 396 guidelines³⁸, missing annotations were imputed to default and distributions were standardized before principal component analysis. Annotations were transformed to PHRED scale with appropriate direction. 397 398 We utilized 4,000 bp windows (N_{variant}≥2, CMAC≥5) separated by 2,000 bp skips. We studied 20.7 million 399 autosomal variants with available functional annotations.

400 As enhancers and promoters, we considered FANTOM5 CAGE profiles reprocessed to the GRCh38 reference genome (https://fantom.gsc.riken.jp/5/)43-45; however, we extended CAGE TSSs to form full-401 length promoters (1,000 bp). We analyzed regulatory regions (Nvariant 2, CMAC 25) with the STAAR R 402 403 package³⁸, using only allele frequencies as variant annotations, which allowed us to include more autosomal variants. With low-frequency variants, 184,192 promoters and 24,045 enhancers were analyzed, resulting 404 in multiple testing corrected significance thresholds *p*-value $<2.9\times10^{-7}$ and *p*-value $<2.6\times10^{-6}$, respectively. 405 For rare variants, the thresholds were p-value $<3.5\times10^{-7}$ and p-value $<4.3\times10^{-6}$, respectively. We did not 406 407 report regions with all variants in perfect LD.

408 Regional plots and functional characterization

We produced regional association plots with LocusZoom⁷³ and Gviz R package 1.38.3⁷⁴; and inspected
variant characteristics from GTEx Portal, eQTLGen Consortium (*p*-value<0.05)⁴⁰, RegulomeDB⁷⁵, YUE

411 Lab (<u>http://3dgenome.fsm.northwestern.edu/</u>)⁴¹, and the Ensemble Variant Effect Predictor^{51,52,76}.

412 Functional research on TRPM2-AS promoter

HELA, HEK-293 and HUVEC cells were cultured as per standard protocol. Total RNA was extracted with 413 TRIzolTM Reagent, cDNA synthesized with SuperScriptTM III Reverse Transcriptase, and qPCR performed 414 415 with iTaqTM Universal SYBR® Green Supermix as per manufacturer's protocol (Supplementary Note). 416 TRPM2-AS promoter sequence was PCR amplified from genomic DNA of one FinnDiane participant 417 carrying rs753589764 minor allele, and one participant carrying none of the identified TRPM2-AS rare minor alleles, and cloned on pBV-Luc plasmid (Addgene plasmid #16539). Transfection of TRPM2-AS 418 419 promoter sequence carrying pBV-Luc reporter and renilla luciferase control plasmid was done using 420 FuGENE® HD Transfection Reagent: Four technical repeats each transfection.

421 Single variant replication

We performed GWAS in individuals with T1D using score test (rvtests version)⁶⁵, and calculated statistical power with the genpwr R package 1.0.4⁷⁷. Genotyping was successful for a varying number of individuals depending on the variant. We observed mutation carriers for six variants (**Supplementary Table 18**) and performed single variant analyses similarly with score test. We analyzed one *LRRN1* variant with linear regression (stats R package 4.2.1) and without relatedness adjustment, because the only mutation carrier was missing in the GWAS data i.e., kinship matrix.

428 We attempted general population replication the FinnGen project from release 6 429 (https://www.finngen.fi/en), and selected stroke phenotypes that best matched our definitions 430 (Supplementary Note).

431 Gene aggregate replication

- 432 We performed SKAT-O analyses in FinnDiane GWAS (r^2 >0.80) for T1D specific replication with the
- 433 GMMAT R package 1.3.2⁷⁸, by including also genotyped variants, and imputed missing data to mean (i.e.,
- 434 individuals with missing genotype at a variant). We attempted general population replication from UK
- 435 Biobank WES studies^{30,35}.

436 Sliding-window and regulatory region replication

437 We attempted T1D specific replication with GWAS data ($r^2 > 0.80$) using STAAR R package³⁸.

438 Data availability

Individual-level data for the study participants are not publicly available, because of the restrictions due to the study consent provided by the participant at the time of data collection. The readers may propose collaboration to research the individual level data with correspondence with the lead investigator. Gene aggregate test stroke summary statistics will be provided in the Supplementary Data.

443 Code availability

- 444 We utilized public softwares for the statistical analyses: plink2 (<u>https://www.cog-genomics.org/plink/2.0/</u>),
- 445 metal (<u>http://csg.sph.umich.edu/abecasis/metal/</u>), rvtests (<u>http://zhanxw.github.io/rvtests/</u>), metaSKAT
- 446 (https://cran.r-project.org/web/packages/MetaSKAT/), STAAR-O (https://github.com/xihaoli/STAAR),
- 447 and GMMAT (<u>https://github.com/hanchenphd/GMMAT</u>).

References

- 1. Harjutsalo, V. et al. Presence and Determinants of Cardiovascular Disease and Mortality in Individuals
- 449 With Type 1 Diabetes of Long Duration: The FinnDiane 50 Years of Diabetes Study. *Diabetes Care* 44,
- 450 1885–1893 (2021).
- 451 2. Giorda, C. B. *et al.* Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients. *Stroke* 38, 1154–
 452 1160 (2007).
- 453 3. Sun, H. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for
- 454 2021 and projections for 2045. *Diabetes Res. Clin. Pract.* **183**, (2022).
- 455 4. Forlenza, G. P. & Rewers, M. The epidemic of type 1 diabetes: what is it telling us? *Curr. Opin.*
- 456 Endocrinol. Diabetes Obes. **18**, 248–251 (2011).
- 457 5. Harjutsalo, V., Sund, R., Knip, M. & Groop, P.-H. Incidence of type 1 diabetes in Finland. *Jama* **310**,
 458 427–428 (2013).
- 459 6. Ståhl, C. H. *et al.* Glycaemic control and excess risk of ischaemic and haemorrhagic stroke in patients
- 460 with type 1 diabetes: a cohort study of 33 453 patients. J. Intern. Med. 281, 261–272 (2017).
- 461 7. Janghorbani, M. *et al.* Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the
- 462 Nurses' Health Study. *Diabetes Care* **30**, 1730–1735 (2007).
- 463 8. Muñoz-Rivas, N. *et al.* Type 2 Diabetes and Hemorrhagic Stroke: A Population-Based Study in Spain
 464 from 2003 to 2012. *J. Stroke Cerebrovasc. Dis.* **25**, 1431–1443 (2016).
- 465 9. Thorn, L. M. *et al.* Clinical and MRI Features of Cerebral Small-Vessel Disease in Type 1 Diabetes.
- 466 *Diabetes Care* **42**, 327–330 (2019).
- 467 10. Putaala, J. *et al.* Diabetes mellitus and ischemic stroke in the young. *Neurology* **76**, 1831–1837
 468 (2011).

- 469 11. Hägg, S. *et al.* Incidence of stroke according to presence of diabetic nephropathy and severe
- diabetic retinopathy in patients with type 1 diabetes. *Diabetes Care* **36**, 4140–4146 (2013).
- 471 12. Dichgans, M., Pulit, S. L. & Rosand, J. Stroke genetics: discovery, biology, and clinical
- 472 applications. *Lancet Neurol.* **18**, 587–599 (2019).
- 473 13. Debette, S. & Markus, H. S. Stroke Genetics: Discovery, Insight Into Mechanisms, and Clinical
- 474 Perspectives. *Circ. Res.* **130**, 1095–1111 (2022).
- 475 14. Mishra, A. *et al.* Stroke genetics informs drug discovery and risk prediction across ancestries.
- 476 *Nature* (2022) doi:10.1038/s41586-022-05165-3.
- 477 15. Malik, R. & Dichgans, M. Challenges and opportunities in stroke genetics. *Cardiovasc. Res.* 114,
 478 1226–1240 (2018).
- 479 16. Lanfranconi, S. & Markus, H. S. COL4A1 mutations as a monogenic cause of cerebral small vessel
 480 disease: a systematic review. *Stroke* 41, e513–e518 (2010).
- 481 17. Ewens, K. G., George, R. A., Sharma, K., Ziyadeh, F. N. & Spielman, R. S. Assessment of 115
- 482 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes 54, 3305–
- 483 3318 (2005).
- Todd, J. A. *et al.* Robust associations of four new chromosome regions from genome-wide
 analyses of type 1 diabetes. *Nat. Genet.* **39**, 857–864 (2007).
- 486 19. Syreeni, A. *et al.* Haptoglobin Genotype Does Not Confer a Risk of Stroke in Type 1 Diabetes.
- 487 *Diabetes* db220327 (2022) doi:10.2337/db22-0327.
- 488 20. Dahlström, E. H. et al. The Low-Expression Variant of FABP4 Is Associated With Cardiovascular
- 489 Disease in Type 1 Diabetes. *Diabetes* **70**, 2391–2401 (2021).
- 490 21. Vujkovic, M. et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular
- 491 outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat. Genet.* 52, 680–691
 492 (2020).

493 22. Ylinen, A. *et al.* The impact of parental risk factors on the risk of stroke in type 1 diabetes. *Acta*494 *Diabetol.* 58, 911–917 (2021).

- 495 23. Antikainen, A. A. V. *et al.* Genome-wide association study on coronary artery disease in type 1
- diabetes suggests beta-defensin 127 as a risk locus. *Cardiovasc. Res.* **117**, 600–612 (2021).
- 497 24. Qi, L. *et al.* Association Between a Genetic Variant Related to Glutamic Acid Metabolism and

498 Coronary Heart Disease in Individuals With Type 2 Diabetes. JAMA **310**, 821–828 (2013).

- 499 25. Fall, T., Gustafsson, S., Orho-Melander, M. & Ingelsson, E. Genome-wide association study of
- 500 coronary artery disease among individuals with diabetes: the UK Biobank. Diabetologia 61, 2174–
- 501 2179 (2018).
- 502 26. Si, Y., Vanderwerff, B. & Zöllner, S. Why are rare variants hard to impute? Coalescent models
 503 reveal theoretical limits in existing algorithms. *Genetics* 217, iyab011 (2021).
- Sandholm, N. *et al.* The Genetic Landscape of Renal Complications in Type 1 Diabetes. *J. Am. Soc. Nephrol.* 28, 557–574 (2017).
- 506 28. Sandholm, N. et al. Whole-exome sequencing identifies novel protein-altering variants
- 507 associated with serum apolipoprotein and lipid concentrations. *Genome Med.* **14**, 132 (2022).
- 508 29. Hu, Y. et al. Whole-Genome Sequencing Association Analyses of Stroke and Its Subtypes in
- Ancestrally Diverse Populations From Trans-Omics for Precision Medicine Project. *Stroke* 53, 875–885
 (2022).
- Jurgens, S. J. *et al.* Analysis of rare genetic variation underlying cardiometabolic diseases and
 traits among 200,000 individuals in the UK Biobank. *Nat. Genet.* 54, 240–250 (2022).
- 513 31. Locke, A. E. *et al.* Exome sequencing of Finnish isolates enhances rare-variant association power.
 514 *Nature* 572, 323–328 (2019).
- 515 32. Thorn, L. M. et al. Metabolic Syndrome in Type 1 Diabetes: Association with diabetic
- 516 nephropathy and glycemic control (the FinnDiane study). *Diabetes Care* **28**, 2019–2024 (2005).

- 517 33. Pei, J., Kinch, L. N., Otwinowski, Z. & Grishin, N. V. Mutation severity spectrum of rare alleles in
- 518 the human genome is predictive of disease type. *PLoS Comput. Biol.* **16**, e1007775 (2020).
- 519 34. Rivas, M. A. et al. Effect of predicted protein-truncating genetic variants on the human
- 520 transcriptome. *Science* **348**, 666–669 (2015).
- 521 35. Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank participants. *Nature* 522 599, 628–634 (2021).
- 523 36. Grami, N. *et al.* Global assessment of Mendelian stroke genetic prevalence in 101 635 individuals
 524 from 7 ethnic groups. *Stroke* 51, 1290–1293 (2020).
- 525 37. Edwards, S. L., Beesley, J., French, J. D. & Dunning, A. M. Beyond GWASs: illuminating the dark
- 526 road from association to function. *Am. J. Hum. Genet.* **93**, 779–797 (2013).
- 527 38. Li, X. et al. Dynamic incorporation of multiple in silico functional annotations empowers rare
- variant association analysis of large whole-genome sequencing studies at scale. *Nat. Genet.* 52, 969–
 983 (2020).
- 530 39. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the
- deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 47, D886–D894 (2019).
- 40. Võsa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and
- polygenic scores that regulate blood gene expression. *Nat. Genet.* **53**, 1300–1310 (2021).
- 41. Wang, Y. et al. The 3D Genome Browser: a web-based browser for visualizing 3D genome
- organization and long-range chromatin interactions. *Genome Biol.* **19**, 151 (2018).
- 536 42. Morris, J. et al. Exploring the Role of Contactins across Psychological, Psychiatric and
- 537 Cardiometabolic Traits within UK Biobank. *Genes* **11**, (2020).
- 43. Andersson, R. *et al.* An atlas of active enhancers across human cell types and tissues. *Nature*539 **507**, 455–461 (2014).

- 540 44. The FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoter-level mammalian
- 541 expression atlas. *Nature* **507**, 462–470 (2014).
- 542 45. Abugessaisa, I. et al. FANTOM5 CAGE profiles of human and mouse reprocessed for GRCh38 and
- 543 GRCm38 genome assemblies. *Sci. Data* **4**, 1–10 (2017).
- 544 46. Fleig, A. & Penner, R. The TRPM ion channel subfamily: molecular, biophysical and functional
- 545 features. *Trends Pharmacol. Sci.* **25**, 633–639 (2004).
- 546 47. Zong, P., Lin, Q., Feng, J. & Yue, L. A Systemic Review of the Integral Role of TRPM2 in Ischemic
- 547 Stroke: From Upstream Risk Factors to Ultimate Neuronal Death. *Cells* **11**, 491 (2022).
- 548 48. Belrose, J. C. & Jackson, M. F. TRPM2: a candidate therapeutic target for treating neurological
- 549 diseases. Acta Pharmacol. Sin. **39**, 722–732 (2018).
- 550 49. Tang, W. H. W. *et al.* Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus:
- 551 Insights From the DCCT/EDIC Study. J. Am. Heart Assoc. 7, e008368 (2018).
- 552 50. DeBose-Boyd, R. A. & Ye, J. SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond. Trends
- 553 Biochem. Sci. 43, 358–368 (2018).
- 554 51. Adzhubei, I. A. *et al.* A method and server for predicting damaging missense mutations. *Nat.*
- 555 *Methods* **7**, 248–249 (2010).
- 556 52. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on
- 557 protein function using the SIFT algorithm. *Nat. Protoc.* **4**, 1073–1081 (2009).
- 558 53. Park, J. *et al.* Mutational characteristics of ANK1 and SPTB genes in hereditary spherocytosis.
- 559 *Clin. Genet.* **90**, 69–78 (2016).
- 560 54. Yan, R. *et al.* A novel type 2 diabetes risk allele increases the promoter activity of the muscle561 specific small ankyrin 1 gene. *Sci. Rep.* 6, 25105 (2016).
- 562 55. Malik, R. *et al.* Multiancestry genome-wide association study of 520,000 subjects identifies 32
- loci associated with stroke and stroke subtypes. *Nat. Genet.* **50**, 524–537 (2018).

- 564 56. Siiskonen, H., Oikari, S., Pasonen-Seppänen, S. & Rilla, K. Hyaluronan Synthase 1: A Mysterious
- 565 Enzyme with Unexpected Functions. *Front. Immunol.* **6**, 1–11 (2015).
- 566 57. Katarzyna Greda, A. & Nowicka, D. Hyaluronidase inhibition accelerates functional recovery
- 567 from stroke in the mouse brain. J. Neurochem. **157**, 781–801 (2021).
- 568 58. Wang, G., Tiemeier, G. L., van den Berg, B. M. & Rabelink, T. J. Endothelial Glycocalyx
- Hyaluronan: Regulation and Role in Prevention of Diabetic Complications. *Am. J. Pathol.* **190**, 781–
 790 (2020).
- 571 59. Zhang, L., Gao, X., Wen, J., Ning, Y. & Chen, Y.-G. Dapper 1 Antagonizes Wnt Signaling by
- 572 Promoting Dishevelled Degradation*. J. Biol. Chem. 281, 8607–8612 (2006).
- 573 60. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence
 574 data. *Bioinformatics* **30**, 2114–2120 (2014).
- 575 61. Van der Auwera, G. & O'Connor, B. *Genomics in the Cloud: Using Docker, GATK, and WDL in*576 *Terra*. (O-Reilly Media, 2020).
- 577 62. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide
- 578 polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3.
- 579 Fly (Austin) **6**, 80–92 (2012).
- 580 63. Salem, R. M. *et al.* Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology
 581 Involved in Glomerular Basement Membrane Collagen. *J. Am. Soc. Nephrol.* **30**, 2000 (2019).
- 582 64. Balding, D. J. & Nichols, R. A. A method for quantifying differentiation between populations at
- 583 multi-allelic loci and its implications for investigating identity and paternity. *Genetica* **96**, 3–12 (1995).
- 584 65. Zhan, X., Hu, Y., Li, B., Abecasis, G. R. & Liu, D. J. RVTESTS: an efficient and comprehensive tool
- for rare variant association analysis using sequence data. *Bioinformatics* **32**, 1423–1426 (2016).
- 586 66. Zhou, X. & Stephens, M. Genome-wide efficient mixed-model analysis for association studies.
- 587 Nat. Genet. 44, 821–824 (2012).

- 588 67. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide
- association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 590 68. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets.
- 591 *Gigascience* **4**, s13742-015 (2015).
- 592 69. Purcell, S. & Chang, C. PLINK v2.00a3LM.
- 593 70. Lee, S. *et al.* Optimal unified approach for rare-variant association testing with application to
- 594 small-sample case-control whole-exome sequencing studies. *Am. J. Hum. Genet.* **91**, 224–237 (2012).
- 595 71. Lee, S., Teslovich, T. M., Boehnke, M. & Lin, X. General framework for meta-analysis of rare
- variants in sequencing association studies. *Am. J. Hum. Genet.* **93**, 42–53 (2013).
- 597 72. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human
- 598 genetic variants. *Nat. Genet.* **46**, 310–315 (2014).
- 599 73. Pruim, R. J. *et al.* LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* 26, 2336–2337 (2010).
- 601 74. Hahne, F. & Ivanek, R. Visualizing genomic data using Gviz and bioconductor. in *Statistical*
- 602 genomics 335–351 (Springer, 2016).
- 603 75. Boyle, A. P. *et al.* Annotation of functional variation in personal genomes using RegulomeDB.
- 604 *Genome Res.* **22**, 1790–1797 (2012).
- 605 76. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
- 606 77. Moore, C. M., Jacobson, S. A. & Fingerlin, T. E. Power and Sample Size Calculations for Genetic
- Association Studies in the Presence of Genetic Model Misspecification. *Hum. Hered.* **84**, 256–271
- 608 (2019).
- 609 78. Chen, H. et al. Efficient Variant Set Mixed Model Association Tests for Continuous and Binary
- Traits in Large-Scale Whole-Genome Sequencing Studies. *Am. J. Hum. Genet.* **104**, 260–274 (2019).

Acknowledgements

611 We are indebted to the late Carol Forsblom (1964–2022), the international coordinator of the FinnDiane 612 Study Group, for his considerable contribution. The skilled technical assistance of Maikki Parkkonen, Heli 613 Krigsman, Mira Rahkonen, Anna Sandelin, and Jaana Tuomikangas is gratefully acknowledged. We also 614 want to acknowledge all the physicians and nurses at each FinnDiane center throughout Finland participating in the recruitment and characterization of the individuals with T1D (Supplementary Table 615 616 20) as well as all the FinnDiane participants. In addition, we acknowledge the participants and investigators of the FinnGen study. We acknowledge that the ELIXIR Finland node, hosted at the CSC - IT Center for 617 618 Science for ICT resources, enabled the WES and WGS data processing. Finally, we want to acknowledge 619 Bert Vogelstein and Jukka Kallijärvi for material provided for the *in vitro* promoter experiments: pBV-Luc plasmids (Bert Vogelstein) and renilla control plasmid (Kallijärvi lab, Folkhälsan Research Center). 620

We utilized data provided by GTEx. The Genotype-Tissue Expression (GTEx) Project was supported by
the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI,
NHLBI, NIDA, NIMH, and NINDS. The data reported here were obtained from the GTEx Portal on
01/04/2022: https://gtexportal.org/home/.

This work was supported by grants from Folkhälsan Research Foundation; Wilhelm and Else Stockmann Foundation; "Liv och Hälsa" Society; Sigrid Juselius Foundation; Helsinki University Central Hospital Research Funds [TYH2018207]; Novo Nordisk Foundation [NNF OC0013659], Academy of Finland [299200 and 316664]; European Foundation for the Study of Diabetes (EFSD) Young Investigator Research Award funds; an EFSD award supported by EFSD/Sanofi European Diabetes Research Programme in Macrovascular Complications; Finnish Foundation for Cardiovascular Research; Sigrid Juselius foundation (220027); and the Finnish Diabetes Research Foundation.

632 Author information

633 Affiliations and contributions.

634 Ethics declaration

635 Ethical approval

- 636 The study protocol has been approved by the ethics committee of the Helsinki and Uusimaa Hospital
- 637 District (491/E5/2006, 238/13/03/00/2015, and HUS-3313-2018), and performed in accordance with the
- 638 Declaration of Helsinki. All participants gave informed consent before participation.

639 Competing interests

P-H G has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board
member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen,
Medscape, Merck Sharp & Dohme, Mundipharma, Nestlé, Novartis, Novo Nordisk and Sanofi; and has
received lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme,
Merck Sharp & Dohme, Medscape, Novartis, Novo Nordisk, PeerVoice, Sanofi, and Sciarc. Other authors
declare no competing interests.

Tables

Table 1. Clinical characteristics of study participants in the next-generation sequencing data sets.

		WES WGS				
	Cases	Controls	<i>p</i> -value	Cases	Controls	<i>p</i> -value
Ν	74	406		112	459	
Hemorrhagic/Ischemic	22/49			26/64		
CVD death <2017 (yes/no, % yes)	35/39 (47%)	66/340 (16%)	2.92×10 ⁻⁸	58/54 (52%)	83/376 (18%)	2.61×10 ⁻¹²
Sex (male/female, % males)	39/35 (53%)	182/224 (45%)	0.25	80/32 (71%)	236/223 (51%)	0.00013
Age (years)	48.39 (11.89)	60.69 (11.13)	7.08×10 ⁻¹³	51.08 (10.29)	58.70 (9.61)	3.52×10 ⁻¹¹
T1D duration (years)	33.6 (10.45)	47.49 (9.84)	5.89×10 ⁻¹⁸	36.16 (9.81)	46.00 (8.14)	6.34×10 ⁻¹⁸
Calendar year of T1D onset*	1969.5 (11.75)	1968 (11)	0.29	1968 (10.25)	1969 (9)	0.80
T1D onset age (years)	14.79 (6.64)	13.21 (7.27)	0.066	14.92 (8.93)	12.69 (7.75)	0.016
Weighted mean HbA _{1c} (%)*	9.00 (2)	8.51 (1.4)	0.0037	8.86 (1.76)	8.34 (1.57)	0.00097
HbA _{1c} count*	19 (28.5)	29 (26)	0.0038	19 (30)	29 (30)	0.011
DKD (yes/no, yes-%)	52/22 (70%)	201/205 (50%)	0.00098	87/25 (78%)	206/253 (45%)	2.49×10 ⁻¹⁰

Weighted mean HbA1c is calculated until the stroke event or the end of follow-up. DKD = end-stage renal disease (ESRD), macro- or microalbuminuria. Mean (standard deviation, SD), *Median (interquartile range, IQR). Student's t-test, Wilcoxon signed rank test or Fisher's exact test.

SNP ID	Position	Potential	Data	REF	MAF	N _{Hom}	OR [95% CI]	I ²	<i>p</i> -value	GWAS OR	FinnGen OR
		target gene		/AL I						(p-value)	(p-value)
Additive model	(minimal adjustment)		1				1				
rs376936219	4:170784011	AADAT,	WGS	G/T	4.6%	-	4.77 [2.66-8.60]	-	1.67×10 ⁻⁷	0.88 (0.35)	1.03 (0.34)
rs4435704	4:170787127	MFAP3L,	WGS	T/C	3.7%	-	6.04 [3.12-11.67]	-	8.83×10 ⁻⁸	-	-
rs4401420	4:170787143	GALNTL6	WGS	C/T	4.1%	-	5.16 [2.79-9.55]	-	1.76×10 ⁻⁷	-	-
Additive	(DKD										
model	adjustment)										
rs114001633	17:17819659	SREBF1 (p.Pro227Leu)	++	G/A	0.3%	-	3804.35 [189.15- 76515.45]	35%	7.30×10 ⁻⁸	1.41 (0.30)	1.03 (0.87)
Recessive	(minimal										
model	adjustment)										
rs2224123	14:24313752	LTB4R*	++	A/T	14.1%	26	16.75 [5.59- 50.17]	77%	4.77×10 ⁻⁷	0.97 (0.92)	1.03 (0.052)
rs1728177	17:43605161	DHX8, MEOX1, ETV4*	WGS	G/A	26.3%	46	6.94 [3.60-13.37]	-	7.19×10 ⁻⁹	1.03 (0.87)	0.99 (0.59)
Recessive	(DKD										
model	adjustment)										
rs76073237	1:160870594	ITLN1, CD244	WGS	GTA/G	36.7%	66	4.69 [2.58-8.54]	-	4.00×10 ⁻⁷	-	-

Table 2.	Lead	variants	discovered	with	single	variant	association	analyses.
					<u> </u>			2

Multiple variants reported from a locus if the lead variant was unavailable in GWAS replication (in such case, we report the closest variants). If the variant was discovered already in the minimal model, we do not report DKD adjusted results. Variants are in Hardy-Weinberg equilibrium (p-value>0.05). N_{Hom}=Number of recessive carriers, ++Meta-analysis with positive minor allele effect direction, *Multiple eQTLs (Supplemental Table 18) or dorsolateral prefrontal cortex PCHi-C links. REF=Reference allele, ALT=Alternative allele, $I^2=Meta$ -analysis heterogeneity estimate, OR=Odds ratio, CI=confidence interval.

Table 3. Protein altering- and protein truncating variants in significant stroke risk genes according to significance thresholds corrected by the number of genes within designated models.

					Sequencing		FinnD	FinnDiane GWAS		en GWAS
Gene (Model)	SNP ID	Consequence (SIFT/PolyPhen)	REF/ALT	MAC	OR [95% CI]	<i>p</i> -value	MAC	OR (p-value)	MAC	OR (p-value)
HASI	19:51713664	p.Tyr500* (-/-)	G/T	-/2	0.31 [0.0050-18.88]	0.57				
(Minimal: PTV	19:51713853	p.Cys437* (-/-)	G/T	-/1	0.32 [0.00062-162.99]	0.72				
≤1%)	rs1396240967	Splice donor (-/-)	C/T	-/1	901.45 [3.53- 230240.57]	0.016				
	rs58597876	Splice donor (-/-)	C/CACAC ACACACA	3/-	369.81 [17.90-7640.36]	0.00013				
LRRN1	rs755350940	5 prime UTR (-/-)	C/T	2/1	4.45 [0.17-114.63]	0.37	20	1.05 (0.93)	1483	0.98 (0.85)
(Minimal + DKD:	rs142381203	p.Arg185Cys (0.00/0.79)	C/T	1/-	67.29 [0.67-6787.51]	0.074	1	0.82 (0.46**)		
$PAV \leq 1\%$)	rs147007969	p.Thr190Ile (0.18/0.54)	C/T	2/4	33.55 [3.92-287.48]	0.0014	25	0.75 (0.61)	1431	0.94 (0.57)
	rs141825989	p.Arg305Cys (0.01/0.80)	C/T	-/1	439.22 [2.19-88150.42]	0.025	1	0.52 (0.81*)		
	rs770349026	p.Arg390His (0.00/0.98)	G/A	-/2	28.22 [0.44-1817.11]	0.12				
	rs747455683	p.Thr442Met (0.12/0.65)	C/T	1/-	2351.95 [6.73- 821987.12]	0.0094			281	0.75 (0.35)
	rs543878366	p.Glu481Lys (0.01/0.27)	G/A	-/1	0.32 [0.00049-216.02]	0.74				
ANK1	rs750580242	p.Ser896Arg (0.40/0.11)	A/T	1/-	24.02 [0.35-1656.73]	0.14				
(Minimal: PAV < 5%)	rs751965455	p.Met1607Ile (0.06/0.07)	C/T	-/1	0.29 [0.0017-49.02]	0.64				
IAV _570)	rs146416859	p.Arg1577Cys (0.03/0.01)	G/A	1/1	6.18 [0.20-194.73]	0.30	15	1.66 (0.49)	716	1.01 (0.94)
	rs34664882	p.Ala114Val (0.04/0.74)	G/A	13/15	3.16 [1.14-8.76]	0.028	141	1.12 (0.63)	8250	0.93 (0.17)
	rs199760447	p.Val1450Ile (1.00/0.00)	C/T	-/1	5229.13 [11.67- 2344071.66]	0.0060	6	0.26 (0.24)	257	1.12 (0.70)
	rs201439151	p.Tyr1386His (0.01/0.50)	A/G	2/1	0.28 [0.016-4.63]	0.37	11	0.73 (0.71)	917	0.76 (0.062)
	rs10093583	p.Met159Val (0.40/0.00)	T/C	4/2	2.62 [0.33-20.88]	0.36	41	0.80 (0.61)	2757	1.03 (0.72)
	rs779805849	p.Val136Glu (0.00/0.99)	A/T	3/-	3.48 [0.15-78.91]	0.43	5	24.19 (0.017)	684	0.85 (0.34)
	rs148275567	p.Arg89Cys (0.00/1.00)	G/A	3/4	8.50 [1.36-53.12]	0.022	11	0.98 (0.98)	1056	0.85 (0.23)
	rs117516263	Structural interaction variant (-/-)	G/A	19/12	0.87 [0.35-2.17]	0.77	114	1.39 (0.22)	6980	0.92 (0.11)
	rs202226361	p.Val1048Met (0.00/1.00)	C/T	5/-	0.84 [0.099-7.09]	0.87	21	3.30 (0.055)	1510	1.01 (0.97)
	rs767717861	p.Thr1022Met (0.00/0.93)	G/A	-/1	11695.97 [20.42- 6698538.99]	0.0038				
	8:41696385	p.Pro302Thr (0.00/1.00)	G/T	-/3	0.30 [0.012-7.50]	0.46				
	8:41696393	p.Ala299Glu (1.00/0.91)	G/T	-/3	6.74 [0.21-211.38]	0.28				
	rs2304877	p.Arg619His (0.01/0.003)	C/T	32/41	1.35 [0.72-2.54]	0.35	317	1.00 (0.98)	20065	1.00 (0.91)
	rs61753679	Structural interaction variant (-/-)	G/T	20/22	0.92 [0.40-2.08]	0.84	120	1.21 (0.47)	8343	0.99 (0.79)
	rs34387324	Structural interaction variant (-/-)	G/A	1/2	0.30 [0.012-7.35]	0.46	10	1.10 (0.92)	1206	1.19 (0.18)
	rs142690258	p.Asn528Ser (0.84/0.001)	T/C	7/5	4.25 [0.99-18.25]	0.051	21	0.69 (0.55)	2327	0.97 (0.72)
	rs140085544	p.Val463Ile (0.04/0.38)	C/T	1/2	143.88 [4.63-4468.82]	0.0046	17	2.43 (0.20)	1101	0.93 (0.60)
	rs769619019	p.Met476Leu (0.11/0.99)	T/A	-/1	0.30 [0.0015-58.17]	0.65				
	rs1015648649	p.Ala461Val (0.00/1.00)	G/A	1/-	0.31 [0.0010-94.56]	0.69				
	8:41717683	p.His442Arg (0.00/1.00)	T/C	1/-	0.31 [0.00099-99.04]	0.69				
	rs1364511169	p.His416Arg (1.00/1.00)	T/C	1/-	0.27 [0.0025-29.56]	0.59				
	rs61735313	p.Asn251Lys (0.01/1.00)	G/T	11/4	4.11 [1.08-15.61]	0.038	77	0.82 (0.53)	3998	0.99 (0.85)
UACA	rs781623644	p.Gln1116* (-/-)	G/A	2/3	154.93 [9.27-2590.28]	0.00045	7	0.51 (0.57)	301	1.10 (0.72)
(Mınımal + DKD: PTV≤1%)	rs185763236	Splice donor (-/-)	C/A	1/-	234.86 [1.47-37624.10]	0.035	1	4084.69 (0.0030*)		

*Genotyped, **Genotyped and tested without kinship adjustment. Consequence: Amino acid alteration matching the SIFT score, SIFT=0-1 (deleterious-tolerated), and PolyPhen=0-1 (bening-damaging); if multiple transcript alterations, we report the most severe consequence score, i.e., PolyPhen score may not

match consequence. MAC=MAC in WGS / MAC in WES, REF=Reference allele, ALT=Alternative allele, OR=Odds ratio, CI=confidence interval.

Figures

Fig. 1: Study design. We studied whole exome- (WES) and whole genome sequencing (WGS) in individuals with T1D. We performed additive and recessive single-variant analyses (MAC \geq 5) across the genome, using fixed-effects meta-analysis for variants available in both data sets, with a minimal adjustment setting i.e., the calendar year of diabetes onset, sex and two first genomic data principal components, and repeated the analyses with an additional DKD adjustment. We conducted gene aggregate analyses with minimal adjustment separately for protein altering variants (PAVs) and protein truncating variants (PTVs); and repeated the analyses with an additional DKD adjustment. Furthermore, we conducted minimally adjusted intergenic aggregate analyses within genomic windows by statistically up-weighting functionally important and rare variants; and within established enhancers and promoters, by weighting variants according to their rarity. We performed stroke subtype association analyses for lead findings.

	Sliding-windows	Enhancers	Promoter	Exon 1	Gene	Exon	2
WGS WES	ACTGTGATCGAACACAGATGTCGATGCTGAT	ACATACCACATAGACACAGATA	IGCCACACACATGATACA	GATATAGACGATGCC GATATAGACGATGCC	CGATATCGCGCGTA	AGATAG <mark>C</mark> TGA AGATAGCTGA	ATCGACT
	Single variant analysis Firth logistic regression			→ Score test fix	ed-effects meta-	analysis	
	Aggregate test analysis	 → Aggregate tests regions (CAGE p 1. Enhancers a. MAF <1% b. MAF <5% 2. Promoters (TSS extended a. MAF <1% b. MAF <5% 	on regulatory beaks): ed until 1000 bp)	 SKAT-O gene Protein alta a. MAF <1 b. MAF <5 2. Protein tru a. MAF <1 b. MAF <5 	aggregate tests ering variants % ncating variants % %	:	

Fig. 2: Additive single variant analysis with minimal adjustment. A. Manhattan plot, B. LocusZoom plot of 4q33.1-34 (LD structure according to a nearby variant, rs4386563).



Fig. 3: Discovered genes with the SKAT-O gene aggregate tests. A. Minimal adjustment, B. Additional adjustment for diabetic kidney disease. The color indicates the $-\log_{10}(p$ -value), with darker color indicating more significant finding. Only the rare variant model (MAF \leq 1%) is reported, if no low-frequency variants (1%<MAF≤5%) were available in the gene. Bonferroni corrected significance thresholds: 4×10⁻⁶ (protein altering variant, PAV≤1%), 4×10⁻⁶ (PAV≤5%), 5×10⁻⁵ (protein truncating variant, PTV≤5%), and 7×10⁻⁵ (PTV≤1%). Number of variants and cumulative minor allele count (MAC) given based on the combined stroke phenotype.



medRxiv preprint doi: https://doi.org/10.1101/2022.11.30.22282752; this version posted December 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Fig. 4: Variants in significant stroke-associated genes after multiple testing correction (SKAT-O). *Diabetic kidney disease adjusted stroke model.



40



Fig. 5: STAAR sliding-window analyses. A. MAF≤5% (inserted QQ-plot without the 4q33-34.1 region), and **B.** MAF≤1%.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.30.22282752; this version posted December 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Extended Data Figures

Extended Data Fig 1. Statistical power in replication

Statistical power to replicate low-frequency (MAF=5%, MAF=1%) and rare (MAF=0.5%, MAF=0.1%) variants with the number of patients in FinnDiane GWAS replication (N=3,945, N_{cases} =367) using different alpha levels: **A.** Nominal significance (0.05), **B.** Multiple testing corrected threshold (0.01), **C.** Multiple testing corrected threshold (0.005), **D.** Multiple testing corrected threshold (0.005).



Extended Data Fig 2. Single variant analysis with DKD adjustment

Stroke single variant analysis Manhattan plot (Firth regression or score test fixe-effects meta-analysis).



Extended Data Fig 3. Recessive single variant analyses

Stroke recessive autosomal single variant analysis Manhattan plots (Firth regression or score test fixedeffects meta-analysis): A. Minimal adjustment, and B. An additional DKD adjustment.



Extended Data Fig 4. SKAT-O minimal model Manhattan plot

A. Protein altering variant (PAV) $\leq 1\%$, B. PAV $\leq 5\%$, C. Protein truncating variant (PTV) $\leq 1\%$, D. PTV≤5%.



Extended Data Fig 5. SKAT-O with additional DKD adjustment Manhattan plot

A. Protein altering variant (PAV) ≤1%, **B.** PAV≤5%, **C.** Protein truncating variant (PTV) ≤1%, **D.** PTV≤5%.



medRxiv preprint doi: https://doi.org/10.1101/2022.11.30.22282752; this version posted December 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Extended Data Fig 6. Known Mendelian stroke-risk genes in T1D

A. SKAT-O p-value, B. Nvariant (MAC) in SKAT-O. Results presented with minimal adjustment.



Extended Data Fig 7. Annotation PCA within functional classes

A. Conservation, B. Epigenetics, C. microRNA, D. Mutation density, E. Protein function, F. Transcription factor, G. Proximity to transcription start- and end sites. Variance explained by the corresponding annotation principal component (aPC) is presented at Dimension 1.



Extended Data Fig 8. Stroke enhancer association Manhattan plot

Variants weighted with PHRED scale minor allele frequencies. A. MAF ≤5%, and B. MAF ≤1%.



Extended Data Fig 9. Stroke promoter association Manhattan plot

Variants are weighted with PHRED scale minor allele frequencies. A. MAF <5%, and B. MAF <1%.



medRxiv preprint doi: https://doi.org/10.1101/2022.11.30.22282752; this version posted December 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Extended Data Fig 10. TRPM2-AS regional plot and experimental data

A. Regional plot of *TRPM2* and *TRPM2-AS* extended region; the discovered promoter is highlighted (red). **B.** *TRPM2-AS* expression in HELA, HEK-293 and HUVEC cell lines, **C.** Relative expression of *TRPM2-AS* and *TRPM2* transcripts in HELA cells (hypoxanthine phosphoribosyltransferase 1 used as reference transcript to normalize quantitative RT-PCR), **D.** Firefly/Renilla luciferase assay of promoter activity. Empty vector (mean=1.0, 12 technical repeats) as transfection control for baseline luciferase activity was compared to *TRPM2-AS* control promoter, i.e., major allele in all identified *TRPM2-AS* variants (mean=56.5, 11 technical repeats, *p*-value=0.00022); which was further compared to a *TRPM2-AS* promoter with rs753589764 minor allele (mean=72.6, 11 technical repeats, *p*-value=0.27): All cloned before firefly reporter gene to evaluate potential transcriptional promoter activity. Statistical significance was assessed with Student's t-test and error bars represent standard error.

